Sermorelin

Ten publications from 1984 to 2023 are cited, and half of them are analytical chemistry. Five papers from 2021 to 2023 develop or validate methods for detecting sermorelin and related GHRH analogues in urine and other biological samples, several of them for anti-doping laboratories. Three rat studies from 1984, 1986 and 1991 examine the structure and pituitary activity of the 1-29 fragment and its analogues, and a 2005 study examines release of the peptide from a polymer matrix. The remaining paper, from 2021, concerns recurrent glioma.

Among the analytical papers, a 2022 study found that sermorelin and its metabolite degrade rapidly in urine above 4 °C or below pH 7, a 2023 study found a sermorelin fragment stable enough to serve as an internal standard, and another 2023 method was validated against World Anti-Doping Agency technical documents. In rats, a 1984 study reported substituted analogues of the 1-29 amide that were up to about 12 times more potent than the parent peptide, and a 1986 study compared 30 analogues substituted at positions 1 to 10 for their interaction with GRF and VIP receptors. A 1991 rat study found that prior administration of the rat 1-29 amide cut the growth hormone response to a later dose of either form by more than half, while the response to the full-length peptide was repeatable. The 2005 study found that only a small fraction of the released peptide reached the blood, though enough to raise circulating growth hormone detectably.

The 2021 glioma paper is a computational prediction from tumour gene-expression data, in which no patient received sermorelin, and no other citation tests it. Beyond it, the cited work contains no human outcome data: the pharmacology comes from rat studies of the 1980s and early 1990s, the formulation work is one study, and the recent literature is about measuring the peptide in samples rather than about what it does.